Publications by authors named "Karl Yen"

Claim this Profile
P
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.
Gilles Tiraboschi, Kim Papp, Thomas Bieber, Stephan Weidinger, Lisa Beck, Karl Yen

CPT Pharmacometrics Syst Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Evidence Demonstrating the Nondepleting Mechanism of Action of Amlitelimab, an OX40 Ligand Monoclonal Antibody.
James G Krueger, Brian S Kim, Stephan Weidinger, Yoko Kataoka, John T O'Malley, Karl Yen

Acta Derm Venereol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.
Stephan Weidinger, Andrew Blauvelt, Kim A Papp, Adam Reich, Chih-Hung Lee, Karl Yen

Immunotherapy· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
Stephan Weidinger, Andrew Blauvelt, Kim A Papp, Adam Reich, Chih-Hung Lee, Karl Yen

J Allergy Clin Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study.
Dedee F Murrell, Frédéric Caux, Aikaterini Patsatsi, Owen Hagino, Lidia Rudnicka, Karl Yen

J Invest Dermatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.
Francesco Muntoni, Barry J Byrne, Hugh J McMillan, Monique M Ryan, Brenda L Wong, Karl Yen

Neurol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials.
Laurent Servais, Karl Yen, Maitea Guridi, Jacek Lukawy, David Vissière

J Neuromuscul Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
Eric L Simpson, Carsten Flohr, Lawrence F Eichenfield, Thomas Bieber, Howard Sofen, Karl Yen

J Am Acad Dermatol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.
Philip Korenblat, Edwin Kerwin, Igor Leshchenko, Karl Yen, Cecile T J Holweg

Respir Med· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
Nicola A Hanania, Michael Noonan, Jonathan Corren, Phillip Korenblat, Yanan Zheng, Karl Yen

Thorax· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
Jane C Davies, Claire E Wainwright, Gerard J Canny, Mark A Chilvers, Michelle S Howenstine, Karl Yen

Am J Respir Crit Care Med· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
Patrick A Flume, Theodore G Liou, Drucy S Borowitz, Haihong Li, Karl Yen

Chest· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
J P Clancy, Steven M Rowe, Frank J Accurso, Moira L Aitken, Raouf S Amin, Karl Yen

Thorax· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
Bonnie W Ramsey, Jane Davies, N Gerard McElvaney, Elizabeth Tullis, Scott C Bell, Karl Yen

N Engl J Med· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis